Cellectis Statistics
Total Valuation
Cellectis has a market cap or net worth of $260.21 million. The enterprise value is $142.52 million.
Important Dates
The next estimated earnings date is Monday, May 11, 2026, after market close.
| Earnings Date | May 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Cellectis has 72.59 million shares outstanding. The number of shares has increased by 10.73% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 72.59M |
| Shares Change (YoY) | +10.73% |
| Shares Change (QoQ) | -1.36% |
| Owned by Insiders (%) | 2.19% |
| Owned by Institutions (%) | 16.38% |
| Float | 46.68M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.27 |
| Forward PS | 3.84 |
| PB Ratio | 3.43 |
| P/TBV Ratio | 3.45 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.79 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.62, with a Debt / Equity ratio of 1.14.
| Current Ratio | 1.62 |
| Quick Ratio | 1.59 |
| Debt / Equity | 1.14 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -4.08 |
Financial Efficiency
Return on equity (ROE) is -65.33% and return on invested capital (ROIC) is -10.83%.
| Return on Equity (ROE) | -65.33% |
| Return on Assets (ROA) | -5.84% |
| Return on Invested Capital (ROIC) | -10.83% |
| Return on Capital Employed (ROCE) | -18.48% |
| Weighted Average Cost of Capital (WACC) | 16.78% |
| Revenue Per Employee | $358,527 |
| Profits Per Employee | -$304,473 |
| Employee Count | 222 |
| Asset Turnover | 0.22 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -423,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +158.33% in the last 52 weeks. The beta is 2.85, so Cellectis's price volatility has been higher than the market average.
| Beta (5Y) | 2.85 |
| 52-Week Price Change | +158.33% |
| 50-Day Moving Average | 3.68 |
| 200-Day Moving Average | 3.44 |
| Relative Strength Index (RSI) | 47.73 |
| Average Volume (20 Days) | 52,160 |
Short Selling Information
The latest short interest is 350,861, so 0.66% of the outstanding shares have been sold short.
| Short Interest | 350,861 |
| Short Previous Month | 388,537 |
| Short % of Shares Out | 0.66% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 7.20 |
Income Statement
In the last 12 months, Cellectis had revenue of $79.59 million and -$67.59 million in losses. Loss per share was -$0.67.
| Revenue | 79.59M |
| Gross Profit | 79.59M |
| Operating Income | -33.08M |
| Pretax Income | -68.02M |
| Net Income | -67.59M |
| EBITDA | -21.75M |
| EBIT | -33.08M |
| Loss Per Share | -$0.67 |
Full Income StatementBalance Sheet
The company has $206.38 million in cash and $86.69 million in debt, with a net cash position of $119.69 million or $1.65 per share.
| Cash & Cash Equivalents | 206.38M |
| Total Debt | 86.69M |
| Net Cash | 119.69M |
| Net Cash Per Share | $1.65 |
| Equity (Book Value) | 75.90M |
| Book Value Per Share | 1.05 |
| Working Capital | 90.49M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$39.40 million and capital expenditures -$2.36 million, giving a free cash flow of -$41.76 million.
| Operating Cash Flow | -39.40M |
| Capital Expenditures | -2.36M |
| Depreciation & Amortization | 11.33M |
| Net Borrowing | -16.19M |
| Free Cash Flow | -41.76M |
| FCF Per Share | -$0.58 |
Full Cash Flow StatementMargins
Gross margin is 100.00%, with operating and profit margins of -41.56% and -84.92%.
| Gross Margin | 100.00% |
| Operating Margin | -41.56% |
| Pretax Margin | -85.45% |
| Profit Margin | -84.92% |
| EBITDA Margin | -27.33% |
| EBIT Margin | -41.56% |
| FCF Margin | n/a |
Dividends & Yields
Cellectis does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -10.73% |
| Shareholder Yield | -10.73% |
| Earnings Yield | -25.98% |
| FCF Yield | -16.05% |
Analyst Forecast
The average price target for Cellectis is $8.50, which is 149.27% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $8.50 |
| Price Target Difference | 149.27% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | 18.61% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Cellectis has an Altman Z-Score of -0.76 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.76 |
| Piotroski F-Score | 2 |
